BACKGROUND: The evidence regarding correlations between various anthropometric characteristics and breast cancer risk among young women is mixed, and few studies have assessed these associations by subtype. METHODS: This was a population-based, case-control study of 779 women with estrogen receptor (ER)-positive breast cancer; 182 women with ER-negative/human epidermal growth factor-2 (HER2)-negative/progesterone receptor-negative (triple-negative [TN]) breast cancer; and 60 women with ER-negative/HER2-overexpressing, invasive breast cancer ages 20 to 44 years who were diagnosed from 2004 to 2010 in the Seattle-Puget Sound metropolitan area; as well as 939 cancer-free controls. Associations between height and body mass index (BMI) at different time points in relation to breast cancer risk were assessed using polytomous logistic regression. RESULTS: Height, BMI at age 18 years, and BMI at the reference date were not related to the risks of ER-positive, TN, or HER2-overexpressing breast cancer. Changes in BMI from age 18 years to the reference date were not related to the risk of either ER-positive or HER2-overexpressing breast cancer. However, compared with women who had a BMI change from 0 to 4.9 kg/m(2) from age 18 years to the reference date, those who experienced a BMI increase ≥10 kg/m(2) during the same interval had a 2.0-fold (95% confidence interval, 1.2-fold to 3.3-fold increase) increased risk of TN breast cancer. For women with ER-positive disease, there was some evidence that parity modified the effect of BMI change (Pinteraction = .002), because a BMI increase of ≥10 kg/m(2) was associated with a reduced risk of ER-positive disease only among nulliparous women (odds ratio, 0.3; 95% confidence interval, 0.2-0.6). CONCLUSIONS: The correlations appear to differ substantially between BMI change and the risks of TN breast cancer and ER-positive breast cancer.
BACKGROUND: The evidence regarding correlations between various anthropometric characteristics and breast cancer risk among young women is mixed, and few studies have assessed these associations by subtype. METHODS: This was a population-based, case-control study of 779 women with estrogen receptor (ER)-positive breast cancer; 182 women with ER-negative/human epidermal growth factor-2 (HER2)-negative/progesterone receptor-negative (triple-negative [TN]) breast cancer; and 60 women with ER-negative/HER2-overexpressing, invasive breast cancer ages 20 to 44 years who were diagnosed from 2004 to 2010 in the Seattle-Puget Sound metropolitan area; as well as 939 cancer-free controls. Associations between height and body mass index (BMI) at different time points in relation to breast cancer risk were assessed using polytomous logistic regression. RESULTS: Height, BMI at age 18 years, and BMI at the reference date were not related to the risks of ER-positive, TN, or HER2-overexpressing breast cancer. Changes in BMI from age 18 years to the reference date were not related to the risk of either ER-positive or HER2-overexpressing breast cancer. However, compared with women who had a BMI change from 0 to 4.9 kg/m(2) from age 18 years to the reference date, those who experienced a BMI increase ≥10 kg/m(2) during the same interval had a 2.0-fold (95% confidence interval, 1.2-fold to 3.3-fold increase) increased risk of TN breast cancer. For women with ER-positive disease, there was some evidence that parity modified the effect of BMI change (Pinteraction = .002), because a BMI increase of ≥10 kg/m(2) was associated with a reduced risk of ER-positive disease only among nulliparous women (odds ratio, 0.3; 95% confidence interval, 0.2-0.6). CONCLUSIONS: The correlations appear to differ substantially between BMI change and the risks of TN breast cancer and ER-positive breast cancer.
Authors: Amanda I Phipps; Diana S M Buist; Kathleen E Malone; William E Barlow; Peggy L Porter; Karla Kerlikowske; Ellen S O'Meara; Christopher I Li Journal: Ann Epidemiol Date: 2012-02-25 Impact factor: 3.797
Authors: Mia M Gaudet; Michael F Press; Robert W Haile; Charles F Lynch; Sally L Glaser; Joellen Schildkraut; Marilie D Gammon; W Douglas Thompson; Jonine L Bernstein Journal: Breast Cancer Res Treat Date: 2011-06-11 Impact factor: 4.872
Authors: A Trentham-Dietz; P A Newcomb; B E Storer; M P Longnecker; J Baron; E R Greenberg; W C Willett Journal: Am J Epidemiol Date: 1997-06-01 Impact factor: 4.897
Authors: G Fagherazzi; N Chabbert-Buffet; A Fabre; G Guillas; M-C Boutron-Ruault; S Mesrine; F Clavel-Chapelon Journal: Int J Obes (Lond) Date: 2011-03-22 Impact factor: 5.095
Authors: Z Huang; S E Hankinson; G A Colditz; M J Stampfer; D J Hunter; J E Manson; C H Hennekens; B Rosner; F E Speizer; W C Willett Journal: JAMA Date: 1997-11-05 Impact factor: 56.272
Authors: P H Lahmann; M Schulz; K Hoffmann; H Boeing; A Tjønneland; A Olsen; K Overvad; T J Key; N E Allen; K-T Khaw; S Bingham; G Berglund; E Wirfält; F Berrino; V Krogh; A Trichopoulou; P Lagiou; D Trichopoulos; R Kaaks; E Riboli Journal: Br J Cancer Date: 2005-09-05 Impact factor: 7.640
Authors: Anne K Swisher; Jame Abraham; Daniel Bonner; Diana Gilleland; Gerald Hobbs; Sobha Kurian; Mary Anne Yanosik; Linda Vona-Davis Journal: Support Care Cancer Date: 2015-03-01 Impact factor: 3.603
Authors: Rebecca H Johnson; Carey K Anders; Jennifer K Litton; Kathryn J Ruddy; Archie Bleyer Journal: Pediatr Blood Cancer Date: 2018-08-28 Impact factor: 3.167
Authors: Kimberly A Bertrand; Traci N Bethea; Lucile L Adams-Campbell; Lynn Rosenberg; Julie R Palmer Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-18 Impact factor: 4.254
Authors: Jennifer D Brooks; Esther M John; Lene Mellemkjaer; Charles F Lynch; Julia A Knight; Kathleen E Malone; Anne S Reiner; Leslie Bernstein; Xiaolin Liang; Roy E Shore; Marilyn Stovall; Jonine L Bernstein Journal: Cancer Med Date: 2016-10-03 Impact factor: 4.452
Authors: Carolina Ortega-Olvera; Alfredo Ulloa-Aguirre; Angélica Ángeles-Llerenas; Fernando Enrique Mainero-Ratchelous; Claudia Elena González-Acevedo; Ma de Lourdes Hernández-Blanco; Elad Ziv; Larissa Avilés-Santa; Edelmiro Pérez-Rodríguez; Gabriela Torres-Mejía Journal: Breast Cancer Res Date: 2018-08-09 Impact factor: 6.466
Authors: Manuel Picon-Ruiz; Cynthia Morata-Tarifa; Janeiro J Valle-Goffin; Eitan R Friedman; Joyce M Slingerland Journal: CA Cancer J Clin Date: 2017-08-01 Impact factor: 508.702